Buy Rating for Structure Therapeutics, Inc.: Potential Disruption in Obesity Treatment with Amylin Agonists
Wall Street analyst Patrick Dolezal from LifeSci Capital maintained a Buy rating on Structure Therapeutics, Inc. with a $72.00 price target, citing the potential of their small molecule amylin agonists in obesity treatment. The company's lead candidate, ACCG-2671, is set for trials by 2025, with promising efficacy in weight loss. BMO Capital also reiterated a Buy rating with a $100.00 target, highlighting the company's potential to disrupt the obesity treatment market.
Tip Ranks·